The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis
BMC Psychology – January 02, 2026
Source: OpenAlex
Summary
Psilocybin shows promise in clinical psychology for cancer patients. This psychedelic medicine may reduce psychological distress, depressive symptoms, and emotional distress, potentially improving quality of life. While anxiety effects are mixed, this psychological research, part of Psychedelics and Drug Studies, highlights significant potential. Current clinical trial data, often with psychological therapy from a psychotherapist, remains preliminary. Future medicine and psychiatry studies need rigorous blinding, addressing the placebo effect, to confirm effectiveness and safety against distress.
Abstract
Psilocybin may reduce depressive symptoms in cancer patients, with mixed effects on anxiety and time-dependent improvements in spiritual well-being and (in single-arm data) quality of life. Given the small number of studies, high heterogeneity, challenges with blinding/expectancy, and frequent co-intervention with psychotherapy, these findings are preliminary. Larger, rigorously blinded trials are needed to determine clinical effectiveness and safety.